Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.06)
# 507
Out of 4,876 analysts
226
Total ratings
42.47%
Success rate
14.69%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $2.77 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.12 | +26.58% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $106.90 | +40.32% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $103.36 | +48.03% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $12.44 | +12.54% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $23.27 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $14.09 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $11.63 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $31.98 | +81.36% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $28.81 | +49.25% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.16 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.08 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $125.42 | +23.58% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.41 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $14.10 | +148.23% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.78 | +171.97% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.15 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.30 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.55 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.20 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.78 | +56.11% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $29.96 | +66.89% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $4.72 | +5.93% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.49 | +708.90% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.17 | +241.88% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $32.40 | +79.01% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.01 | +10,791.09% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $3.76 | +2,027.66% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.41 | +112.77% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $9.48 | +16.03% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.24 | +45.72% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.37 | +2,537.36% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.15 | +830.23% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $14.54 | +1,275.52% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.30 | +1,224.50% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $1.75 | +1,271.43% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.11 | +6,724.64% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.49 | +168.46% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $52.21 | -25.30% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $73.22 | -79.51% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.54 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.50 | +5,042.86% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.77
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.12
Upside: +26.58%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $106.90
Upside: +40.32%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $103.36
Upside: +48.03%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $12.44
Upside: +12.54%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.27
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.09
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.63
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $31.98
Upside: +81.36%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $28.81
Upside: +49.25%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.16
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.08
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $125.42
Upside: +23.58%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $14.10
Upside: +148.23%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.78
Upside: +171.97%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.15
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.30
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.55
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.20
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.78
Upside: +56.11%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $29.96
Upside: +66.89%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $4.72
Upside: +5.93%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.49
Upside: +708.90%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.17
Upside: +241.88%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $32.40
Upside: +79.01%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.01
Upside: +10,791.09%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $3.76
Upside: +2,027.66%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.41
Upside: +112.77%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $9.48
Upside: +16.03%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.24
Upside: +45.72%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.37
Upside: +2,537.36%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.15
Upside: +830.23%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $14.54
Upside: +1,275.52%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.30
Upside: +1,224.50%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $1.75
Upside: +1,271.43%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.11
Upside: +6,724.64%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.49
Upside: +168.46%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $52.21
Upside: -25.30%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $73.22
Upside: -79.51%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.54
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.50
Upside: +5,042.86%